Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease exhibiting variable clinical course and survival rates. Mutational status of the immunoglobulin heavy chain variable regions (IGHVs) of CLL cells offers useful prognostic information for high-risk patients, but time and economical costs originally prevented it from being routinely used in a clinical setting. Instead, alternative markers of IGHV status, such as zeta-associated protein (ZAP70) or messenger RNA levels are often used. We report a 1 H-NMR-based metabolomics approach to examine serum metabolic profiles of early stage, untreated CLL patients (Binet stage A) classified on the basis of IGHV mutational status or ZAP70. Metabolic profiles of CLL patients (n ¼ 29) exhibited higher concentrations of pyruvate and glutamate and decreased concentrations of isoleucine compared with controls (n ¼ 9). Differences in metabolic profiles between unmutated (UM-IGHV; n ¼ 10) and mutated IGHV (M-IGHV; n ¼ 19) patients were determined using partial least square discriminatory analysis (PLS-DA; R 2 ¼ 0.74, Q 2 ¼ 0.36). The UM-IGHV patients had elevated levels of cholesterol, lactate, uridine and fumarate, and decreased levels of pyridoxine, glycerol, 3-hydroxybutyrate and methionine concentrations. The PLS-DA models derived from ZAP70 classifications showed comparatively poor goodness-of-fit values, suggesting that IGHV mutational status correlates better with diseaserelated metabolic profiles. Our results highlight the usefulness of 1 H-NMR-based metabolomics as a potential non-invasive prognostic tool for identifying CLL disease-state biomarkers.
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Introduction
Chronic lymphocytic leukaemia (CLL) exhibits heterogeneous clinical behaviour with patient survival times ranging from months to decades. 1, 2 Although about one-third of patients exhibit aggressive disease onset and require immediate treatment, another one-third have long survival rates and never require treatment. 3 The remaining one-third are characterised by an initial indolent phase followed by disease progression. Disease staging systems developed by Rai 4 and Binet, 5 which enable classification of patients into good, intermediate and poor prognostic outcome groups have facilitated the determination of treatment course. However, neither provide the means for early stage diagnosis nor the discrimination of stable and progressive forms of CLL. 6 Accordingly, much attention has recently been directed toward the identification of early disease prognostic markers capable of predicting stable or progressive forms of the disease.
The mutational status of the immunoglobulin heavy chain variable region (IGHV) gene of CLL cells offers useful prognostic information. Patients with leukaemic cells carrying unmutated IGHV (UM-IGHV) genes show poor prognosis 7, 8 and reduced survival rates and response to chemotherapy. 9, 10 Initially, time and economical costs associated with IGHV sequencing, combined with the fact that it could not be performed in most diagnostic laboratories, drove the search for alternate markers for IGHV mutational status. Genetic profiling of CLL revealed that the 70-kDa zeta-associated protein (ZAP70) could be used robustly as an alternative marker of mutational status. 11 Assessment of ZAP70 expression level by flow cytometry [12] [13] [14] and RT-PCR 15, 16 is now the often used marker of IGHV mutational status.
Although the aforementioned genomic and transcriptomic approaches have proven beneficial for identifying gene and messenger RNA species differences in CLL patient groups, 11, 17, 18 they are to some extent limited by the static nature of genome and by the fact that messenger RNA levels do not always correlate with protein concentration or biochemical function. 19 For example, CD38 expression has been proposed as an additional marker of CLL prognosis and assessment of its expression levels by flow cytometry seems to have prognostic merit. [20] [21] [22] However, CD38 remains unchanged at the level of the transcriptome in CLL patients. 11 Changes in metabolites and small molecules involved in biochemical processes offer a more functional reflection of a biological system. Metabolic profiling techniques (for example, gas/liquid chromatography mass spectrometry (MS), nuclear magnetic resonance (NMR)) combined with multivariate statistics (interchangeably termed 'metabolomics' or 'metabonomics') offer the ability to examine global changes in metabolites associated with phenotypic changes. 23, 24 Thus, metabolomics is a powerful approach for examining disease-related metabolic changes and accordingly is effective for the identification of new biomarkers, [25] [26] [27] and as a potential prognostic tool in its own right. [28] [29] [30] Some recent studies have highlighted the potential for metabolomics analysis of blood samples for the detection of cancers, including epithelial ovarian 31 and oral 32 (using a 1 H-NMR-based platform), as well as prostate cancers 33 (using a mass spectrometry-based platform).
In this study, we have used a 1 H-NMR-based metabolomics approach to examine serum metabolic profiles of early stage, untreated CLL patients (Binet stage A) classified on the basis of IGHV mutational status or ZAP70 (measured by flow cytometry or real time quantitative PCR (RT-qPCR)).
1 H-NMR-based metabolomics is particularly advantageous in a clinical setting because it can be performed on standard serum or plasma samples in a rapid, non-invasive manner enabling recovery of sample. 34 Importantly, NMR spectroscopy is inherently quantitative with measured peak intensities being directly correlated to concentration. 35 Specifically, we aimed to determine whether 1 H-NMR-based metabolomics can be used to identify disparate serum metabolic 'fingerprints' in patients exhibiting either UM-IGHV or M-IGHV mutational status. We also evaluated metabolic models of patients classified by ZAP70 to evaluate which of these correlate better with the underlying metabolic fingerprint of the patient group.
Materials and methods

Patient cohort and classification
All experimental procedures were approved by the ethics and research committees of the Centro de Investigació n Príncipe Felipe, Valencia, Spain and Hospital Arnau de Vilanova, Valencia, Spain in accordance with institutional guidelines. After obtaining informed consent, a total of 29 serum samples were collected from previously untreated CLL patients (Binet stage A) for inclusion in this study (see Table 1 ). An additional nine control samples were collected from healthy donors. Clinical diagnosis of patients was performed using standard morphological and immunophenotypic criteria. For classification of samples, IGHV mutational status along with ZAP70 flow cytometry assays and RT-qPCR were performed on all samples as previously described by our group. 17, 36 For this, genomic DNA was prepared from cryopreserved cells and IGHV gene rearrangements were amplified in duplicate by multiplex PCR using a mixture of heavy chain variable region framework 1 (VHFR1; VH1-VH6) family primers in combination with a consensus heavy chain joining region (JH) primer, as designed by the BIOMED-2 Concerted Action 37, 38 and according to the recommendations of the ERIC group (European Research Initiative on CLL, http://www.ericll.org). 39 After amplification, PCR products were purified and directly sequenced. Sequencing analysis was started using the consensus JH primer as the sequencing primer on PCR products from the two independent reactions. After the identification of the involved VH family member through the ImMunoGeneTics (IMGT) database (http:// imgt.cines.fr/IMGT_vquest/vquest), the PCR products were sequenced with the appropriate VHFR1 family primer for confirmation. A consensus sequence was made from the aligned sequences and compared with sequences in the IMGT database. We considered the samples with 498% homology with the closest germinal line as unmutated. Flow cytometry of ZAP70 was undertaken using a modified protocol described by Crespo et al. 12 with an isotype control used as a negative control. Samples exhibiting X20% homology were considered positive. The RT-qPCR-based amplification for ZAP70 was performed using Hs00277148 m1 primers and probe set (TaqMan Gene Expression Assays, Applied Biosystems, Foster City, CA, USA) and normalised to the GUS gene. Values of ZAP70 higher than 0.1050 were considered to be positive. 15 
Sample preparation
To avoid the introduction of any analytical bias due to sample preparation, all samples were collected from patients of the Service of Hematology of the Arnau de Vilanova Hospital, Valencia, Spain and were processed consistently in the following manner. Venous blood samples were collected in the morning preprandial, after overnight fasting, using vacuum tubes (BD vacutainer; no additive; 8.5 ml; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and left at room temperature to coagulate for 45 min. After this, samples were centrifuged at 1000 g for 10 min. Serum was collected and immediately stored at À80 1C until being used for metabolomic analysis. Preparation of serum samples for metabolomics analysis by 1 H-NMR was performed manually according to Beckonert et al. 40 After defrosting at room temperature, 200 ml of serum was mixed with 400 ml of 0.9% saline solution (wt/vol, NaCl in 90% H 2 0/10% D 2 O) and then centrifuged at 12 000 g for 5 min at 4 1C. After this, 550 ml of the supernatant was added to a 5-mm NMR tube and NMR acquisition was performed immediately.
NMR acquisition
The NMR spectra were acquired using a Bruker Avance II 600 spectrometer (Bruker Biospin, Rheinstetten, Germany) equipped with a TCI cryoprobe operating at 600.13 MHz for 1 H. Samples were afforded 5 min within the spectrometer to equilibrate before acquisition. The 1 H-NMR spectra of serum samples were collected at a constant temperature of 300 K (27 1C) using the relaxation edited Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence 41 to facilitate the detection of low molecular weight species. A total of 256 free induction decays (FIDs) were collected into 64-K data points over a spectral width of 20 p.p.m. A 3-s relaxation delay was incorporated between FIDs during which a continual water presaturation radio frequency (RF) field of 35 Hz was applied. Receiver gain was kept at a constant value of 32 and the total spin-spin relaxation delay was 40 ms. For quantitative purposes, nuclear Overhauser effect spectroscopy (NOESY) spectra were acquired using the same parameters as the CPMG experiment with the exception of 128 FIDs being collected with a mixing time of 10 ms. The FID values were multiplied by an exponential function equivalent to that of a 1.0-Hz linebroadening factor and then were Fourier transformed. All spectra were phased and baseline corrected automatically using TopSpin (v 2.1, Bruker BioSpin, Rheinstetten, Germany). Spectra were then visually inspected and manually adjusted where necessary. Spectra were calibrated internally to the anomeric proton signal of a-glucose at chemical shift
Metabolite assignments were performed using Amix (v 3.8.3, Bruker BioSpin) in combination with the Bruker NMR Metabolic Profiling Database (BBIOREFCODE 2.0.0, Bruker BioSpin), and if needed, with reference to any available assignments in the literature. 42, 43 To facilitate metabolite identification two-dimensional experiments were also acquired. Two-dimensional J-resolved 1 H-NMR experiments (J-res) were run and four FIDs were accumulated for each of the 40 increments acquired. Spectral widths were set at 16.7 p.p.m. and 78 Hz for F2 and F1, respectively. Relaxation delay was set at 1.5 s during which the water signal was eliminated using a presaturation sequence. After processing, one-dimensional skyline projections and the full two-dimesional J-res spectra were used for assignment. Twodimensional 1 H, 13 C-HSQCs (Heteronuclear Single-Quantum Coherence) were also run for representative samples. A total of 128 FIDs were acquired for each of the 256 increments. Spectral widths were set at 16 and 150 p.p.m. for 1 H and 13 C, respectively. Water signal was eliminated using a presaturation continuous wave during the 1.5 s relaxation delay.
Data processing and statistical analysis
Each region of the NMR spectra corresponding to a discernable, well resolved signal (present in at least 50% of all samples in a given patient group) or signal groups were selected and integrated in Amix using the variable-sized bucketing module. Variable-sized bucketing enables each integral, or bucket, to have an individual size, allowing signals with larger shifts (for example, signals derived from lipids) to be compiled into broader buckets. This method reduces chemical shift alterations caused by factors such as pH and ionic strength variability between samples. Purified metabolite 1 H-NMR profiles derived from the BBIOREFCODE (Bruker Biospin) were used to facilitate the selection of variable-sized regions for integration. Both singlets and multiplets of the same metabolite were used where possible for identification and integration. Buckets were normalised to the sum of total spectral intensity to minimise possible differences in serum concentration between samples and to reduce any residual minor chemical shift alterations. 44, 45 Data were subjected to multivariate analysis in the form of unsupervised principal components analysis (PCA) and supervised partial least squares-discriminate analysis (PLS-DA) using SIMCA-P (Soft independent modelling of class analogies-P; v 11.5, Umetrics, Umeå, Sweden). Data were scaled to unit variance by dividing each variable by 1/(S k ), where S k represents the s.d. value of the variable. This method of scaling was used as it applies equal weight to all variables regardless of their absolute value, ensuring that all variables retain equal importance during the generation of the model. In PCA, the first principal component represents the largest amount of correlated variation in the data set. The second principal component (representing the second largest amount of correlated variation in the data set) is placed orthogonally to the first, and so on, until an adequate description of the data set is achieved. The first three principal components were plotted in two and three-dimensional score plots and examined for any clustering trends. Corresponding loading plots were used to identify those metabolites responsible for any contribution to separation observed. To better examine differences in the underlying metabolic profiles of the sample groups, supervised multivariate analysis in the form of PLS-DA was used. The PLS-DA analysis is an extension of PCA, in which the algorithm is provided with class membership of samples and components are projected and rotated around the axis to obtain maximum separation between classes, or in other words, provide the best description of classrelated variability. The PLS-DA models were evaluated using the goodness-of-fit parameter (R 2 Y) and the predictive ability parameter (Q 2 Y), which was calculated by a seven-round internal cross-validation of R 2 Y. R 2 Y represents the proportion of variance explained by a given component in the model, whereas Q 2 Y is defined as the proportion of variance in the data predictable by the PLS-DA model under cross-validation. 46, 47 As an additional measure of PLS-DA model validity, permutation testing was conducted to evaluate whether the specific classification of two classes in a model was significantly better than any other random classification in two arbitrary groups. 46 Score contribution weights were calculated for threecomponent PLS-DA models and were examined to determine which variables were most responsible for any observed separation between groups. 46 Those metabolites exhibiting the greater weightings (scaled in units of s.d.) were responsible for observed separation between groups. All other results presented are described as mean±s.e.m. Statistical significance of the data was determined using the non-parametric Mann-Whitney U test or analysis of variance (Tukey-Kramer post hoc test), where appropriate. P-values o0.05 were considered to be significant.
NMR quantification
Concentration measurements of metabolites of interest in all samples were performed using the recently implemented Bruker 'Digital ERETIC' (digital electronic reference to access in vivo concentrations) tool package that is based on the ERETIC 48 and PULCON 49 (pulse length-based concentration determination) methods. Briefly, this method uses a reference sample of known concentration to first calibrate a digital ERETIC signal that is then added at a chosen frequency in the reference spectrum. Second, this signal is added to the spectrum of an unknown sample and multiplied by a scaling factor that takes into account the variations in pulse lengths between the reference and the unknown sample (PULCON principle). Thus, absolute concentration values of metabolites in a complex sample can be accurately determined using the known concentration of an unrelated, external reference sample. This method is particularly advantageous as it avoids issues of nonspecific interactions between commonly used internal standards, such as trimethylsilylpropionate and proteins present in the blood serum sample. 50 The Digital ERETIC signal was generated in both NOESY and CPMG spectra at a chemical shift of 11.0 p.p.m. (to avoid overlap of existing signals) and calibrated for both experiments using a standard solution of 2 mM sucrose prepared in 90% H 2 0/ 10% D 2 O. Owing to potential binding of lipids to proteins in the serum, we used the NOESY experiment for the quantification of cholesterol and clinical assay data for the quantification of lipoproteins (low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and high-density lipoprotein). The CPMG experiment was used for the quantification of the remaining metabolites as any error potentially introduced by this relaxation-edited experiment would be less compared with the error introduced by large overlapped signals derived from proteins and large molecules in the NOESY spectra. Furthermore, any reduction in signal intensity induced by differential relaxation effects would be consistent across samples, thus relative changes in concentration values would remain accurate. Importantly, the linewidth of metabolite signals used for quantification did not vary between samples, indicating that these metabolites are not affected by protein/lipid binding. To calculate the concentration of a given metabolite referenced to the Digital ERETIC signal, we used the following formula:
where [met] is the concentration of a given metabolite in mM; I met the intensity of the signal derived from the integrated metabolite; n met the number of hydrogen nuclei present in the metabolite signal integrated; [ERETIC] the equivalent concentration value according to the sucrose calibration standard in mM; and I ERETIC is the intensity value of the Digital ERETIC signal integrated.
Results
In this study, we compared the metabolic profiles of 38 serum samples collected from 9 healthy controls and 29 CLL (Binet stage A, untreated) patients (see Table 1, Supplementary  Table 1) . Consistent with epidemiological studies, the incidence of CLL was higher in males (n ¼ 18) compared with females (n ¼ 11) in our data set. 51 The average age of the patient (71.0±2.0 years) and control groups (63.4±3.9 years) encroached statistical significance (P ¼ 0.08). To examine whether any age-related metabolic differences existed in our subject groups, PCA of the metabolic fingerprints of control and patient subjects was performed. No age-or sex-related groupings were observed in the PCA score plots, indicating that the majority of variance in the data is not related to any possible metabolic differences in subject age (see Supplementary Figures 1 and 2) . The IGHV somatic mutation status was determined for the CLL patients with 19 positive (M-IGHV: 9 females, 10 males) and 10 negative (UM-IGHV: 3 females, 7 males) samples detected. The expression of ZAP70, as determined by flow cytometry, was positive in 12 CLL patients and negative in the other 15 participants. In comparison, ZAP70 as assessed by real time quantitative PCR (RT-qPCR) was positive for only 10 cases. Results for ZAP70 could not be obtained for two patients by flow cytometry due to the bad quality of the peripheral blood mononuclear cells obtained in both samples; however, these samples could be assessed by RT-qPCR. Furthermore, insufficient RNA for RT-qPCR obtained for one patient, prevented testing in this sample but was assessed for ZAP70 by flow cytometry. The 1 H-NMR spectra acquired from human serum samples using a CPMG pulse sequence consisted of signals derived from a complex mixture of primarily metabolites in addition to some low M r lipid and protein species (see Figure 1) . Identified signals included amino acids, metabolic intermediates, saturated and unsaturated triglycerides and fatty acids, N-acetyl glycoproteins and organic acids (see Supplementary Table 2 ). In total, 109 resonances were detected in 1 H-NMR spectra of human serum. Of these, 73 could be assigned to 50 individual compounds using the proprietary BBIOREFCODE and literature references. 42, 43 Signals that could not be unambiguously assigned to known compounds were labelled as 'unknown' and were nevertheless included in the statistical analysis. A total of 109 signals selected for analysis was integrated into variable-sized buckets, normalised to total spectral intensity and imported into SIMCA-P for multivariate analysis.
Initial visual comparison of the 1 H-NMR spectra failed to identify any major differences between CLL patients and healthy controls. Unsupervised analysis of the 1 H-NMR data in the form of PCA showed no indication of group clustering associated with disease status (Figure 2a) , age or gender (see Supplementary  Figures 1 and 2) . Examination of corresponding loading plots revealed that the majority of variation in the first two components was due to the differences in glucose concentrations between patients (data not shown). Thus, to determine whether any disease-related variability existed within the data, PLS-DA was used (Figure 2b ). Three-dimensional plotting of the first three components showed clear separation between CLL patients and healthy controls (for two-dimensional plots, see Supplementary Figure 3a and b). The corresponding loading plot (Figure 2c ) and score contribution weights (Figure 2d ) indicated the metabolites primarily responsible for this separa- tion. Increased concentration of pyruvate, glutamate, proline, pyridoxine and two signals that could not be unambiguously assigned (3.30 and 3.33 p.p.m.), as well as decreased levels of isoleucine in CLL patients compared with controls were primary influences for the separation observed in the PLS-DA model. To determine whether it was possible to distinguish UM-IGHV and M-IGHV patients on the basis of their 1 H-NMR metabolic profile, we first used PCA (Figure 3a) . The PCA score plot of the first three principal components showed a tendency of the UM-IGHV group to cluster in the top right-hand side of the plot. The PLS-DA analysis markedly enhanced the separation of the two patient groups (see Figure 3c ; Po0.025 by permutation testing). The 10 major loadings responsible for the separation observed in the PLS-DA score plot are described in the score contribution weights plot (Figure 3d ; for twodimensional plots, see Supplementary Figure 3c and d) . Serum metabolic profiles of UM-IGHV samples were consistently higher in levels of cholesterol, lactate, uridine, fumarate and (CH 2 ) n signals, derived mainly from fatty-acid side chains in VLDL and LDL. Comparatively lower concentrations of pyridoxine, glycerol, 3-hydroxybutyrate, methionine and a signal from an unknown metabolite (located at 3.37 p.p.m.) were also characteristic of UM-IGHV patients.
We then tested whether similar 1 H-NMR-derived metabolic models could be developed using alternative classification of these patients. Patients were classified on the basis of ZAP70 using flow cytometry or RT-qPCR assay, PLS-DA was performed for each classification method and the goodness-of-fit values were compared (Table 2) . Good model fit (R 2 Y) could be obtained for each classification method using a three-component . Models derived from serum metabolic profiles classified on the basis of ZAP70 flow cytometry or RT-qPCR assays exhibited poor predictive capability and were deemed non-significant by permutation testing.
To validate the statistical modelling of the UM-IGVH and M-IGVH patients groups, quantification of 8 metabolites found to differ between these two groups was performed by NMR (see Table 3 ). Consistent with the PLS-DA model data, higher concentrations of cholesterol, lactate, uridine and fumarate, and lower concentrations of pyridoxine, glycerol, 3-hydroxybutyrate and methionine were detected in UM-IGVH patients. Statistically significant differences were obtained for cholesterol, lactate, methionine and pyridoxine, whereas the remaining metabolite differences approached significance. Clinical data for serum lipoprotein levels were acquired for a subset of the patients examined in this study and assessed on the basis of IGHV mutational status (UM-IGHV, n ¼ 7; M-IGHV, n ¼ 12; see Figure 4 ). Consistent with the 1 H-NMR analysis, higher levels of VLDL were detected in UM-IGHV, concurrent with decreased high-density lipoprotein levels. However, these results were not statistically significant probably due to small sample size. The LDL levels were similar between UM-IGHV and M-IGHV patients.
Discussion
Efforts to understand leukaemia-related metabolism have been made as early as 1939; 52 however, to the best of our knowledge, this paper presents the first global examination of serum-derived metabolites in the context of CLL. We have examined the potential diagnostic capacity of a 1 H-NMR-based metabolomic Table 2 Goodness-of-fit comparisons of PLS-DA models derived using classification by different molecular subgroups Y are presented as cumulative values for the threecomponent model. Significance indicates whether the PLS-DA model formed for that given classification method exhibited statistically significant separation between the two patient groups using permutation testing (50 random reclassifications). Results indicate that within the data set analysed, classification of patients based on IGHV mutational status was more consistent with underlying metabolomic profile differences.
Table 3
Serum concentration values for metabolites responsible for PLS-DA separation between UM-IGVH and M-IGVH patients Abbreviations: IGHV, immunoglobulin heavy chain variable region; M, mutated; NMR, nuclear magnetic resonance; PLS-DA, partial least square discriminatory analysis; UM, unmutated. Metabolites with highest positive or negative score contribution weights for the PLS-DA model were quantified in each serum sample of the data set by NMR. Using the digital ERETIC signal as an externally generated standard, serum concentration values were calculated for both UM-(n ¼ 10) and M-IGVH (n ¼ 19) patients. Differences in metabolite concentrations mirrored those observed in the PLS-DA models with cholesterol, lactate, uridine and fumurate observed to be higher in UM-IGVH patients, whereas glycerol, 3-hydroxybutyrate, methionine and pyridoxine were lower. a Chemical shift of signal used for quantification. Although total cholesterol and low-density lipoprotein (LDL) levels remained unchanged, higher levels of very low-density lipoprotein (VLDL) and decreased levels of high-density lipoprotein (HDL) were observed in UM-IGHV patients.
approach for identifying poor prognosis CLL patients as classified by IGHV mutational status.
As a proof-of-principle experiment, serum metabolic profiles from healthy controls were compared with CLL patients (no treatment, Binet stage A; Figure 2a ). Initial analysis using unsupervised PCA did not indicate any obvious disease-related variation in the metabolic profile. Examination of corresponding loading plots showed that the main variation in the data set was derived from glucose signals. The serum metabolome represents a collective 'snapshot' of metabolic alterations in the biochemical pathways of the entire body induced by a plethora of factors, including disease, life habits (for example, diet, smoking and exercise), gender, drug intake and environmental factors. The mean age (±s.e.m.) of the entire study group was 69 years ( ± 1.8 years) at time of collection, and it is therefore possible that the variation in glucose concentration between samples could reflect a number of underlying and undetected illnesses or lifestyle differences. Thus, to identify CLL-related differences in the serum metabolic fingerprint, PLS-DA was used (Figure 2b) . Priori class information provided to the statistical algorithm enabled disease-related variation in the data set to be better described, resulting in clear separation between controls and CLL patients. Two of the metabolites responsible for the separation were identified as pyruvate and glutamate, with increased serum levels of the former previously described in CLL patients. 53 Evidence suggests pyruvate kinase type M2 may have a role in this observation. Pyruvate kinase type M2 is responsible for transferring phosphate from phosphoenolpyruvate to ADP, resulting in the production of ATP and pyruvate. Its role in cell proliferation, tumour formation and apoptosis is well known. 54, 55 The tumour-specific dimeric form of pyruvate kinase type M2 is released by cancer cells into the bloodstream 56 and in accordance with this, elevated serum levels of pyruvate kinase type M2 have been reported in haematological tumours including CLL. 57 The interaction of pyruvate kinase type M2 with oncoproteins causes a build-up of the phosphometabolites that precede pyruvate kinase. As a result of this, tumour cells typically do not contain an active glycerol 3-phosphate shuttle, meaning their ability to deal with hydrogen produced in the glyceraldehyde 3-phosphate dehydrogenase reaction requires additional pathways. Two such pathways culminate in glutamate production (converted from cytosolic citrate) and fatty-acid synthesis. 58 Both products are released from solid tumours and exhibit the capacity to suppress immune cell function. [59] [60] [61] Decreased activity of pyruvate transaminase, which catalyses the interconversion of glutamate and pyruvate to a-ketoglutarate and alanine, may also account for the increased concentration of these metabolites in CLL patients. Increased serum pyruvate can also be caused by deficiencies in thiamine, the physiologically active form of which, thiamine pyrophosphate, acts as a coenzyme in pyruvate decarboxylation. Seglimann et al. 62 have reported comparatively high rates of thiamine deficiency in CLL patients and have proposed that this may be due to increased whole body requirements of energy and thiamine, increased thiamine consumption by tumour cells and finally, impaired thiamine phosphorylation. Although detectable using 1 H-NMR, serum concentrations of thiamine were too low to be assessed in this study.
Having determined that CLL patients harbour a serum metabolic profile that is distinguishable from healthy controls, we wanted to examine whether similar distinction could be made between a sub-population of CLL patients classified on the basis of IGHV mutational status. Supervised multivariate modelling in the form of PLS-DA enabled good separation of UM-IGHV and M-IGHV patients (see Figure 3) . Both unsupervised (PCA) and PLS-DA statistical analyses indicated that the metabolic profile of one particular M-IGHV patient was more similar to that of UM-IGHV patients. No information available in the clinical notes of the patient indicated a reason as to why this patient would have a metabolic profile markedly difference to the other M-IGHV patients. As the metabolome is more reflective of 'realtime' active biochemical processes, it is tempting to speculate that the metabolic classification of this patient is more representative of the disease status reflected at the time of sample collection. Although future studies using increased sample size and a blind test set of patient samples would probably increase the robustness of the analysis presented here, our results provide evidence that 1 H-NMR-based metabolic profiling harbours the ability to detect differences in the serum metabolome of UM-IGHV and M-IGHV patients, which can be subsequently used for classification purposes.
Differences in serum metabolite concentrations responsible for the separation of the UM-IGHV from the M-IGHV patients included elevated levels of cholesterol derived from VLDL, lactate, uridine, fumarate and (CH 2 ) n signals derived mainly from fattyacid side chains in VLDL and LDL, as well as comparative decreases in glycerol, 3-hydroxybutyrate and methionine (see Figure 3d ). Further validation of this data was performed by quantifying concentrations of these metabolites in each serum sample using NMR (see Table 3 ) or biochemical assays (see Figure 4 ). Changes in metabolite concentrations between UM-and M-IGVH patients mirrored those indicated by PLS-DA models; however, in some cases, statistically significant differences were not obtainedFmost probably because of small sample size. This offers an example of how using univariate analyses exclusively could lead to such metabolites being discarded for further investigation. Contrastingly, the multivariate statistical approaches used in this study, which considers numerous variables (metabolites) across multiple samples and dimensions, facilitates a more global description of the serum metabolic profile of UM-and M-IGVH patients, indicating the potential importance of subtle metabolic differences between the two groups.
Although metabolites displaying statically significant differences between UM-and M-IGVH patient groups represent potential metabolite biomarkers, our results also warrant consideration in the context of previously published data. High membrane fluidity in CLL lymphocytes due to low membrane cholesterol levels, which are reflected in reduced serum cholesterol concentrations, have been reported by a number of groups. [63] [64] [65] In addition, leukaemic leukocytes display substantial increases in sterol synthesis compared with cells isolated from healthy controls. 66, 67 Malignant transformation of lymphocytes to highly proliferative CLL cells surely involves major usage and reorganisation of critical membrane components, such as cholesterol, a molecule transported from the liver through the blood stream primarily in VLDL and LDL. We were able to acquire clinical measurements of serum lipoproteins for a subset of the patients examined in the metabolomics study. Consistent with the 1 H-NMR-based metabolomics analysis, a trend toward increasing serum VLDL levels was observed in UM-IGHV patients (see Figure 4) . The high-density lipoprotein levels tended to be lower in M-IGHV patients, whereas levels of LDL remained unchanged between the two patient groups. Clinical and NMR-derived data collectively indicate that the cholesterol signal increase in UM-IGHV patients is derived mainly from VLDL. Recently, it was reported that female CLL patients, who exhibit a apolipoprotein E4 (apoE4) genotype, have longer survival rates than non-apoE4 patients. 68 ApoE4 is the pro-apoptotic isoform of the apoE glycoprotein present in VLDL particles. Furthermore, they confirmed previous findings that poor-outcome CLL patients express higher levels of lipoprotein lipase mRNAFtranscript of the enzyme responsible for converting VLDL to LDL.
38,69 Although we did not observe an LDL increase in the UM-IGHV patients, modulation of serum lipoproteins seems to have an important functional role in CLL disease progression.
In the same manner by which differences in the metabolic profile of UM-IGHV and M-IGHV patients were identified using multivariate modelling of 1 H-NMR serum profiles, we examined whether similarly descriptive metabolic models could be built using alternative prognostic markers. The PLS-DA models were reconstructed using the classification information of patients on the basis of their ZAP70 status (flow cytometry or RT-qPCR). In all cases, the most robust and predictive model was described by the IGHV mutational status. Moreover, PLS-DA models using the alternative prognostic markers were not significant by permutation testing. Although this does not rule out the potential prognostic value of these alternate markers of CLL, our data supports the commonly held view that IGHV mutations are closely linked to the functional aspects of CLL as described biochemically in the metabolome.
The functional and transient nature of the metabolome makes metabolomic analysis by 1 H-NMR a useful tool for monitoring CLL disease progression and potentially response to treatment. Although the discussion regarding metabolic differences between patient groups in this study is far from exhausted, a metabolomic approach to study CLL may also lead to a better understanding of the biochemical mechanisms involved in disease progression. Although we endeavour to examine the serum metabolome of a larger cohort of CLL patients, our data support the idea that multivariate analysis of 1 H-NMR-derived serum metabolic profiles provides a rapid, minimally invasive tool for diagnosis of CLL and for classification of poor prognosis patients based on IGHV mutation status.
